Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib in Advanced Biliary Tract Carcinoma
NCT04550624Phase 2Completed
- Sponsor
- Shanghai Jiahui International Hospital
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in biliary tract carcinoma (BTC), sponsored by Shanghai Jiahui International Hospital. Started Sep 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT04550624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550624.